Nevertheless, mutations are rare — with a mutational frequency of just 0.6% and 0.5% for cGAS and STING, respectively, among tumours of The Cancer Genome Atlas (TCGA) PanCancer database [1] — and the extent of epigenetic silencing demonstrates a large variation in cGAS and STING promoter methylation in tumour samples compared with corresponding normal tissues. The gene discussed is CGAS; the disease is neoplasm.